SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 56.70-2.2%10:11 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (7790)1/22/2003 2:25:52 PM
From: Biomaven   of 52153
 
tuck,

I don't see that much more label expansion (other than Enbrel for psoriasis/psoriatic arthritis), but their products all still have a fair way to grow from here. I don't think they will have any trouble hitting a 20% growth rate for the next few years.

At some point of course some enterprising company is going to come up with some small molecule drugs that do what Epogen and Neupogen do, and then AMGN will have some problems.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News